IDEAYA Biosciences, Inc. (IDYA)
NASDAQ: IDYA · Real-Time Price · USD
40.11
-1.66 (-3.97%)
Aug 28, 2026, 4:00 PM EDT - Market closed
IDEAYA Biosciences Revenue
IDEAYA Biosciences had revenue of $8.86M in the quarter ending June 30, 2026. This brings the company's revenue in the last twelve months to $234.13M, up 3,244.67% year-over-year. In the year 2025, IDEAYA Biosciences had annual revenue of $218.71M with 3,024.43% growth.
Revenue (ttm)
$234.13M
Revenue Growth
+3,244.67%
P/S Ratio
16.53
Revenue / Employee
$1,614,669
Employees
145
Market Cap
3.87B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 218.71M | 211.71M | 3,024.43% |
| Dec 31, 2024 | 7.00M | -16.39M | -70.07% |
| Dec 31, 2023 | 23.39M | -27.55M | -54.08% |
| Dec 31, 2022 | 50.93M | 22.99M | 82.28% |
| Dec 31, 2021 | 27.94M | 8.40M | 43.01% |
| Dec 31, 2020 | 19.54M | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Legend Biotech | 1.27B |
| Telix Pharmaceuticals | 890.79M |
| Iovance Biotherapeutics | 324.97M |
| Arcus Biosciences | 117.00M |
| AbCellera Biologics | 66.17M |
| Tango Therapeutics | 53.81M |
| Relay Therapeutics | 10.35M |
| Denali Therapeutics | 3.60M |
IDYA News
- 2 days ago - IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 11 days ago - Ideaya Biosciences enters IDE892 collaboration with Genentech - TheFly
- 11 days ago - IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer - PRNewsWire
- 23 days ago - Ideaya Biosciences price target lowered to $42 from $45 at Citizens - TheFly
- 24 days ago - Ideaya Biosciences price target raised to $60 from $58 at Wedbush - TheFly
- 24 days ago - Ideaya Biosciences price target lowered to $59 from $63 at Truist - TheFly
- 25 days ago - Ideaya Biosciences reports Q2 EPS ($1.22), consensus ($1.05) - TheFly
- 26 days ago - IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update - PRNewsWire